Catalog Products »
SARS-CoV-2 Spike protein (RBD, L452R, Avi & His Tag)-HRP
SARS-CoV-2 Spike protein (RBD, L452R, Avi & His Tag)-HRP
| Species | SARS-CoV-2 | ||||||
| Protein Construction |
|
||||||
| Conjugate | HRP | ||||||
| Biological Activity | This protein is validated to bind with human ACE2 (Cat. No. Z03516) in functional ELISA assay. | ||||||
| Expression System | CHO | ||||||
| Application |
The optimal dilution ratio should be determined by the end user for specific applications. ELISA 1:1000 |
||||||
| Formulation | Supplied as a solution in PBS, pH 7.4, 0.1% ProClin 300. | ||||||
| Storage & Stability | Upon receiving, this product remains stable for up to 3 months at 2-8°C. Protect from light. |
SARS-CoV-2 Spike protein (RBD, L452R, Avi & His Tag)-HRP can bind with ACE-2 Fc Chimera, Human (Cat. No. Z03516) in a functional ELISA.
| Target Background | SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage B.1.429, also known as CAL.20C, with S13I, W152C, L452R mutations in the spike proteins, of which the L452R was of particular concern. B.1.429 is possibly more transmissible, but further study is necessary to confirm this. CDC has listed B.1.429 and the related B.1.427 as "variants of concern," and cites a preprint for saying that they exhibit a ~20% increase in viral transmissibility. |
| Synonyms | Lineage B.1.429; CAL.20C; B.1.427 |
| References |
1. Emergence of a novel SARS-CoV-2 strain in Southern California, USA. 2. New California Variant May Be Driving Virus Surge There, Study Suggests. 3. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
For more documents, please visit "Technical Support".
